EGFR and lung carcinoma: Additionally there are EGFR targeting small molecule PROTACs based also on pomalidomide (Figure 1) that have showed selective and potent antitumor activities in EGFR-TKI resistant lung cancer cells and can stimulate necrosis and stop cell cycle in H1975 cells.31